Harmony Biosciences Unveils New Phase 3 ARGUS Trial Data on EPX-100 for Dravet Syndrome
Harmony Biosciences Holdings Inc. announced new data from its Phase 3 ARGUS trial on EPX-100 for Dravet syndrome, to be presented at the 2025 American Epilepsy Society Annual Meeting in Atlanta. The trial is currently enrolling participants, and presentations will include preliminary results and a drug-drug interaction study. This information was originally published by Harmony Biosciences via Business Wire.
Harmony Biosciences Holdings Inc. has announced that new open-label extension data from its ongoing Phase 3 ARGUS trial investigating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome will be presented at the 2025 American Epilepsy Society Annual Meeting. The meeting will take place from December 5 to December 9, 2025, in Atlanta, Georgia. Poster presentations are scheduled for Monday, December 8, with topics including preliminary results from the open-label extension phase of the ARGUS study and a drug-drug interaction study of EPX-100 with clinical probe substrates for selected CYP enzymes. The ARGUS trial is currently enrolling participants. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harmony Biosciences Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251202699766) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
